
|Articles|March 1, 2003
Cannula approach using posterior delivery brings unparalleled safety
Posterior juxtascleral injection of he angiostatic steroid analog anecortave acetate (Alcon) has been associated with a remarkable safety profile in clinical trials evaluating it for the treatment of subfoveal choroidal neorvascularization (CNV) associated with age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
2
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
3
Collarettes common but largely stable in moderate-to-severe dry eye patients
4
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada
5

















































.png)


